Novartis AG (NYSE:NVS), rated #4 in sales found itself at #6 ($4.06 bn EUR) for total research and development budget in 2006. 2007 had goods news from Novartis with FDA and EU approval of osteoporosis drug, Aclasta/Reclast and hypertension drug, tekturna, but its painkiller, prexige, was recalled due to liver related illness.
Novartis currently has 138 drugs in development, 50 which are in Phase II or III testing.
Pipeline breakdown*:
Galvus - Diabetes
Xolair - Allergic Asthma
Anticipated 2008 filings:
QAB149 - COPD
LBH589 - Solid tumors
AGO178 - Depression
Tifacogin - CAP
MFF258 - COPD/Asthma
RAD001 - Solid tumors
Tobramycin - Cystic Fibrosis
Tekturna - Hypertension
Anticipated 2009 filings:
LIC477 (US) - Bipolar disorder
FTY720 - Multiple sclerosis
SOM230 - Cushings / GEP3 tumors
EPO906 - Solid tumors
ACZ885 - Muckle Wells
ABF656 - Hepatitis C
Tasigna - GIST
MycograbTM (US) - Severe fungal infections
Galvus - Diabetes
* Data on the phases of these drugs was not available. The company's pipeline report was broken down according to the anticipated filing date rather than the phase of study.
[Source: FierceBiotech]
.jpg)
» 2007 Edition of the European Commission's Report of R&D Spending from PharmaGazette
The 2007 edition of the European Commission's annual report of research and development spending places Pfizer Inc. at the top of the heap outspending all other industries.Pharmaceuticals and biotechnology became the top R&D spenders beating ou... [Read More]
Tracked on: December 12, 2007 10:52 AM | Permalink to Trackback